DS 3201Alternative Names: DS-3201; DS-3201b
Latest Information Update: 12 Apr 2016
At a glance
- Originator Daiichi Sankyo Inc
- Class Antineoplastics
- Mechanism of Action EZH2 enzyme inhibitors; Histone-lysine N-methyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 01 Mar 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Japan (unspecified route) (NCT02732275)